Table 2

Angiographic and procedural variables and antithrombotic therapies administered in the cath lab

Overall (n=598)AF at admission (n=292)New-onset AF (n=306)P value
Radial approach, n (%)517 (86.5)260 (89.0)257 (84.0)0.07
Multivessel disease, n (%)306 (51.2)140 (48.0)166 (54.3)0.12
Basal TIMI 0/1, n (%)226 (38.1)88 (30.1)138 (45.1)<0.001
Site of PCI, n (%)
 Left main44 (7.4)19 (6.5)25 (8.2)0.44
 Left anterior descending326 (54.5)155 (53.1)171 (55.9)0.49
 Circumflex176 (29.4)82 (28.1)94 (30.7)0.48
 Right coronary artery229 (38.3)116 (39.7)113 (36.9)0.48
 Arterial/venous graft9 (1.5)7 (2.4)2 (0.7)0.08
Type of stent, n (%)
 BMS15 (2.5)9 (3.1)6 (2.0)0.38
 DES, durable polymer363 (60.7)162 (55.5)201 (65.7)0.01
 DES, biodegradable polymer163 (27.3)90 (30.8)73 (23.9)0.06
 DES, polymer-free78 (13.0)47 (16.1)31 (10.1)0.03
 >2 stents implanted, n (%)115 (19.2)53 (18.2)62 (20.3)0.51
 Complete revascularisation, n (%)421 (70.4)206 (70.6)215 (70.3)0.94
Antithrombotic therapies administered in the cath lab, n (%)
 ASA31 (5.2)20 (6.9)11 (3.6)0.07
 DAPT101 (16.9)63 (21.6)38 (12.4)0.003
 GP IIb/IIIa inhibitors69 (11.5)14 (4.8)55 (18.0)<0.0001
 Cangrelor9 (1.5)$ (1.4)5 (1.6)0.23
 Unfractionated heparin333 (55.7)187 (64.0)146 (47.7)<0.0001
  • AF, atrial fibrillation; ASA, acetylsalicylic acid; BMS, bare metal stent; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; GP IIb/IIIa, glycoprotein IIb/IIIa; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.